Core Insights - Yinosh experienced a decline of 2.28% on November 17, with a trading volume of 41.92 million yuan [1] - The company reported a financing net buy of -770,200 yuan on the same day, indicating a negative sentiment among investors [1] - As of November 17, the total margin balance for Yinosh was 61.27 million yuan, which is 1.42% of its market capitalization, reflecting a low financing level compared to the past year [1] Financial Performance - For the period from January to September 2025, Yinosh achieved a revenue of 571 million yuan, representing a year-on-year decrease of 35.33% [2] - The company reported a net profit attributable to shareholders of -14.79 million yuan, a significant decline of 111.14% compared to the previous year [2] Shareholder and Institutional Holdings - As of September 30, 2025, the number of Yinosh shareholders decreased by 9.97% to 4,849, while the average circulating shares per person increased by 257.28% to 18,703 shares [2] - The company has distributed a total of 45.11 million yuan in dividends since its A-share listing [3] - New institutional shareholders include Huatai-PineBridge Healthcare Mixed Fund and Huaxia Stable Growth Mixed Fund, which are now among the top ten circulating shareholders [3]

Core Viewpoint - Yinosh's stock price has experienced fluctuations, with a current price of 47.70 CNY per share, reflecting a year-to-date increase of 35.55% and a recent decline of 2.03% on November 17 [1] Group 1: Financial Performance - For the period from January to September 2025, Yinosh reported a revenue of 571 million CNY, representing a year-on-year decrease of 35.33% [2] - The company recorded a net profit attributable to shareholders of -14.79 million CNY, a significant decline of 111.14% compared to the previous year [2] - Cumulative cash dividends paid by Yinosh since its A-share listing amount to 45.11 million CNY [3] Group 2: Shareholder and Market Activity - As of September 30, 2025, the number of Yinosh shareholders decreased by 9.97% to 4,849, while the average number of circulating shares per person increased by 257.28% to 18,703 shares [2] - Major shareholders include new entrants such as Huatai-PineBridge Healthcare Mixed Fund and Huaxia Stable Growth Mixed Fund, which hold 1.12 million shares and 0.93 million shares respectively [3] - The stock's trading activity shows a net outflow of 628,300 CNY from main funds, with large orders accounting for 13.39% of purchases and 18.12% of sales [1]

Market Overview - The medical services sector declined by 0.47% on November 14, with the digital human sector leading the drop [1] - The Shanghai Composite Index closed at 3990.49, down 0.97%, while the Shenzhen Component Index closed at 13216.03, down 1.93% [1] Stock Performance - Notable declines in individual stocks include: - Digital Human: closed at 17.28, down 4.85% with a trading volume of 80,400 shares and a turnover of 1.411 million [1] - Haoyuan Pharmaceutical: closed at 77.20, down 3.54% with a trading volume of 30,800 shares and a turnover of 2.4212 million [1] - Yinos: closed at 48.69, down 2.62% with a trading volume of 14,300 shares and a turnover of 7132.217 [1] - Other notable declines include Taige Pharmaceutical, MediX, and WuXi AppTec, all showing declines between 1.28% and 2.08% [1] Capital Flow - The medical services sector experienced a net outflow of 238 million yuan from institutional investors, while retail investors saw a net inflow of 181 million yuan [3] - Notable capital flows for specific stocks include: - Ruizhi Pharmaceutical: net inflow of 38.93 million yuan from institutional investors, but net outflows from retail and speculative investors [3] - Chengda Pharmaceutical: net inflow of 37.96 million yuan from institutional investors, with significant outflows from speculative investors [3] - Other stocks like Sanbo Brain Science and Jinyu Medical also showed varying net inflows and outflows among different investor types [3]

Core Viewpoint - Yinosh's stock price has shown significant volatility, with a year-to-date increase of 39.24% and a recent decline of 2.00% on November 14, 2023, indicating potential market fluctuations and investor sentiment [1]. Group 1: Company Overview - Yinosh Biotechnology Co., Ltd. is located in the China (Shanghai) Pilot Free Trade Zone and was established on May 12, 2010, with its listing date set for September 3, 2024 [1]. - The company primarily provides non-clinical research services in the biopharmaceutical sector, with 96.31% of its revenue coming from non-clinical services, 3.42% from clinical services, and 0.27% from other sources [1]. Group 2: Financial Performance - For the period from January to September 2025, Yinosh reported a revenue of 571 million yuan, representing a year-on-year decrease of 35.33%, and a net profit attributable to shareholders of -14.79 million yuan, a decline of 111.14% compared to the previous year [2]. - The company has distributed a total of 45.11 million yuan in dividends since its A-share listing [3]. Group 3: Shareholder and Market Activity - As of September 30, 2025, the number of shareholders decreased by 9.97% to 4,849, while the average number of circulating shares per person increased by 257.28% to 18,703 shares [2]. - Notable changes in institutional holdings include new entries from Huatai-PineBridge Healthcare Mixed Fund and Huaxia Stable Growth Mixed Fund among the top ten circulating shareholders [3].

登录新浪财经APP 搜索【信披】查看更多考评等级 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述或者重大遗漏，并对其内容 的真实性、准确性和完整性依法承担法律责任。 重要内容提示： ●会议召开时间：2025年11月20日（星期四） 16:00-17:00 ●会议召开地点：上海证券交易所上证路演中心（网址：https://roadshow.sseinfo.com/） ●会议召开方式：上证路演中心网络互动 ●会议问题征集：投资者可于2025年11月19日(星期三)16:00前登录上证路演中心网站首页点击"提问预征 集"栏目或通过公司邮箱bo@innostarbio.com进行会前提问，公司将在本次说明会上对投资者普遍关注的 问题进行回答。 本次投资者说明会以网络互动形式召开，公司将针对2025年第三季度的经营成果及财务指标的具体情况 与投资者进行互动交流和沟通，在信息披露允许的范围内就投资者普遍关注的问题进行回答。 二、说明会召开的时间、地点 董事会秘书：李燕女士 独立董事：范国钦先生 （如有特殊情况，参会人员可能进行调整） 四、投资者参加方式 （一）投资者可在2025年11月20日（星期四） ...

登录新浪财经APP 搜索【信披】查看更多考评等级 证券代码：688710 证券简称：益诺思 公告编号：2025-041 上海益诺思生物技术股份有限公司 关于召开2025年第三季度业绩说明会的公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述或者重大遗漏，并对其内容 的真实性、准确性和完整性依法承担法律责任。 重要内容提示： 会议召开时间：2025年11月20日（星期四） 16:00-17:00 会议召开地点：上海证券交易所上证路演中心（网址：https://roadshow.sseinfo.com/） 一、 说明会类型 本次投资者说明会以网络互动形式召开，公司将针对2025年第三季度的经营成果及财务指标的具体情况 与投资者进行互动交流和沟通，在信息披露允许的范围内就投资者普遍关注的问题进行回答。 二、 说明会召开的时间、地点 董事、总裁：常艳女士 财务总监：高晓红女士 董事会秘书：李燕女士 独立董事：范国钦先生 （如有特殊情况，参会人员可能进行调整） 会议召开方式：上证路演中心网络互动 会议问题征集：投资者可于2025年11月19日(星期三)16:00前登录上证路演中心网站首页点击"提问 ...

证券代码：688710 证券简称：益诺思 公告编号：2025-041 上海益诺思生物技术股份有限公司 关于召开 2025 年第三季度业绩说明会的公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性依法承担法律责任。 重要内容提示： 会议问题征集：投资者可于 2025 年 11 月 19 日(星期三)16:00 前登 录上证路演中心网站首页点击"提问预征集"栏目或通过公司邮箱 bo@innostarbio.com 进行会前提问，公司将在本次说明会上对投资者 普遍关注的问题进行回答。 上海益诺思生物技术股份有限公司（以下简称"公司"）已于 2025 年 10 月 31 日发布公司 2025 年第三季度报告，为便于广大投资者更 全面深入地了解公司 2025 年第三季度经营成果、财务状况，公司计 划于 2025 年 11 月 20 日（星期四）16:00-17:00 举行 2025 年第三季度 业绩说明会，就投资者关心的问题进行交流。 一、 说明会类型 会议召开时间：2025 年 11 月 20 日（星期四） 16:00-17:00 会 议 召 开 ...

Core Insights - Yinosh experienced a stock price increase of 10.46% on November 11, with a trading volume of 163 million yuan [1] - The company reported a significant decline in revenue and net profit for the first nine months of 2025, with revenue of 571 million yuan, down 35.33% year-on-year, and a net loss of 14.79 million yuan, a decrease of 111.14% [2] Financing and Trading Activity - On November 11, Yinosh had a financing buy-in amount of 10.01 million yuan and a net financing outflow of 5.66 million yuan, with a total financing balance of 63.92 million yuan, representing 1.41% of its market capitalization [1] - The financing balance is below the 20th percentile of the past year, indicating a low level of financing activity [1] - There were no short sales or repayments on November 11, with the short selling balance at zero, which is at the 90th percentile of the past year, indicating a high level of short selling activity [1] Shareholder and Institutional Holdings - As of September 30, the number of shareholders for Yinosh decreased by 9.97% to 4,849, while the average number of circulating shares per person increased by 257.28% to 18,703 shares [2] - The company has distributed a total of 45.11 million yuan in dividends since its A-share listing [3] - New institutional shareholders include Huatai-PineBridge Healthcare Mixed Fund and Huaxia Stable Growth Mixed Fund, while several funds exited the top ten circulating shareholders list [3]

登录新浪财经APP 搜索【信披】查看更多考评等级 股东询价转让结果报告书暨持股5% 以上股东权益变动触及5% 整数倍的提示性公告 上海张江生物医药基地开发有限公司（以下简称"张江生药基地"或"转让方"）保证向上海益诺思生物技 术股份有限公司（以下简称"益诺思"）提供的信息内容不存在任何虚假记载、误导性陈述或者重大遗 漏，并对其真实性、准确性和完整性依法承担法律责任。 本公司及董事会全体成员保证公告内容与信息披露义务人提供的信息一致。 重要内容提示: ●本次询价转让的价格为35.49元/股，转让的股票数量为4,229,388股。 ●公司控股股东、实际控制人、董事、监事及高级管理人员不参与本次询价转让。 ●本次转让不会导致公司控股股东、实际控制人发生变化。 证券代码：688710 证券简称：益诺思 公告编号：2025-040 上海益诺思生物技术股份有限公司 本次转让导致权益变动的，转让方上海张江生物医药基地开发有限公司持股比例由10.82%减少至 7.82%。 一、转让方情况 (一)转让方基本情况 截至2025年10月31日，转让方所持公司股份的数量、比例情况如下： ■ 本次询价转让的转让方为持股5%以上的股东， ...

Core Viewpoint - The report details a shareholding reduction by Shanghai Zhangjiang Biopharmaceutical Base Development Co., Ltd. in Shanghai Yinos Biotech Co., Ltd., decreasing its stake from 10.82% to 7.82% through a block trade of 4,229,388 shares at a price of 35.49 yuan per share, which does not affect the company's control or governance structure [6][15][20]. Group 1: Shareholding Changes - The information disclosure obligor held 15,250,141 shares before the transaction, representing 10.82% of the total shares, and after the transaction, it holds 11,020,753 shares, which is 7.82% of the total [5][6]. - The share reduction was executed through an inquiry transfer method, and the shares transferred cannot be sold by the buyer for six months [3][6]. - The transaction does not lead to a change in the company's controlling shareholder or actual controller [8][15]. Group 2: Transaction Details - The inquiry transfer price was set at 35.49 yuan per share, with the total number of shares transferred being 4,229,388 [15][20]. - The transfer was conducted without participation from the company's controlling shareholders, directors, supervisors, or senior management [15]. - The inquiry process involved 224 institutional investors, with 17 submitting valid bids, resulting in 15 investors receiving allocations [18][20]. Group 3: Compliance and Reporting - The information disclosure obligor confirmed that the report contains no false records, misleading statements, or significant omissions, and it assumes legal responsibility for the report's content [2][11]. - The report complies with relevant laws and regulations, ensuring a fair and transparent transfer process [20].